FCER2

Across TCGA pan-cancer cohorts, FCER2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of FCER2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where FCER2 RNA is repressed in tumor relative to normal tissue. In most cancer types FCER2 is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and BRCA are the cancer types where FCER2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FCER2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	−1.629	<.001	11	view →
COAD	Female	II,III,IV	−1.549	<.001	11	view →
BRCA	All	II,III,IV	−0.843	<.001	8	view →
KICH	All	All	−0.243	.001	5	view →
LUSC	All	All	−0.491	.005	4	view →
READ	All	II,III,IV	−1.997	.037	2	view →
PAAD	Male	All	−1.255	.026	2	view →
THCA	All	All	−0.781	.011	2	view →
UCEC	All	All	−0.237	.022	2	view →
HNSC	Male	All	−0.202	.031	2	view →
STAD	Female	III,IV	+3.955	.035	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

FCER2–BLCA

Open the BLCA breakdown →